Quantitative real time-polymerase chain reaction method in Bcr-Abl translocation diagnostics

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 318-322

  Stankov, Karmen ^a   Mihajlovic, D ^a   Stanimirov, B ^a   Stankov, S ^b   Bajin Katic, K ^a   Mikov, I ^c   Popovic, S ^c  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b University Novi Sad   (Serbia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Diagnostics; Gene translocations; Leukemia; qRT PCR

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA;

ARTICLE; CHRONIC MYELOID LEUKEMIA; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADENINE; AMINO ACID SEQUENCE; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; DNA PRIMERS; DNA, COMPLEMENTARY; EXONS; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MUTAGENESIS, INSERTIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 77954410584     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C. Trends in mortality from leukemia in subsequent age groups. Leukemia 2000; 14: 1980-1985.
2. Sallmyr A, Fan J, Rassool FV. Genomic instabihty in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008; 270: 1-9.
3. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002; 2: 1-10.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005; 105: 2640-2653. (Pubitemid 40446252)
5. Lee A, Kirk J, Edmands S, Radich J. Multiplex PCR of bcr-abl Fusion Transcripts in Philadelphia Positive Acute Lymphoblastic Leukemia. PCR Methods Appl 1995; 4: 283-287.
6. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367. (Pubitemid 28492345)
7. Biernaux C, Loos M, Seis A, Huez G, Stryckmans P. Detection of Major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.
8. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
9. Van Etten R. Mechanisms of transformation by the Bcr-Abl oncogene: new perspectives in the post-imatinib era. Leukemia Res 2004; 28: s21-s28. (Pubitemid 38251495)
10. Stankov K, Stankov S, Popovic S. Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition. Med Oncol 2009; 26: 437-444
11. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology. Am Soc Hematol Educ Program, 2009: 477-487.
12. Saldanha J, Silvy M, Beaufils N et al. Characterization of a reference material for Bcr-Abl (m-Bcr) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 2007; 21: 1481-1487.
13. Takahashi M, Matsuda F, Margetic N, Lathrop M. Automated identification of single nucleotide polymorphisms from sequencing data. J Bioinform Comput Biol 2003; 1: 253-265.
14. Radich JP, Gooley T, Bryant E et al. The significance of bcr-abl molecular detection in chronic myeloid leukaemia patients "late", 18 months or more after transplantation. Blood 2001; 98: 1701-1707.
15. Guang Zhang J, Lin F, Chase A, Goldman JM, Cross NCR Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996; 87: 2588-2593. (Pubitemid 26086906)
16. Thomas DA, Faderl S, Cortes J et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396-4407.
17. Hochhaus A, Drucker B, Sawyers C. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039-1043.
18. Milojkovic D, Apperley J. State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 2008; 20: 112-121. (Pubitemid 350190990)
19. Sahay T, Schiffer CA. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. Curr Opin Hematol 2008; 15: 134-139. (Pubitemid 351323154)
20. Gullo CA, Chuah CT, Hwang WYK, Gerrard KH. Detection and quantification of the Abelson tyrosine kinase domains of the bcr-abl gene translocation in chronic myeloid leukaemia using genomic quantitative real-time polymerase chain reaction. Ann Acad Med Singapore 2006; 35: 680-687.
21. Strnad M, Brajuskovic G, Strelic N et al. Expression of programmed cell death proteins in patients with chronic myeloid leukemia. J BUON 2008; 13: 403-408.